Tower Research Capital LLC TRC Purchases 5,884 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Tower Research Capital LLC TRC lifted its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 626.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,823 shares of the biopharmaceutical company’s stock after buying an additional 5,884 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Revance Therapeutics were worth $60,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. DCF Advisers LLC lifted its holdings in shares of Revance Therapeutics by 869.3% during the fourth quarter. DCF Advisers LLC now owns 256,872 shares of the biopharmaceutical company’s stock worth $2,258,000 after buying an additional 230,372 shares in the last quarter. Rhenman & Partners Asset Management AB raised its stake in Revance Therapeutics by 31.6% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 475,872 shares of the biopharmaceutical company’s stock worth $4,183,000 after purchasing an additional 114,193 shares in the last quarter. CIBC Asset Management Inc grew its position in shares of Revance Therapeutics by 251.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,147,294 shares of the biopharmaceutical company’s stock worth $10,085,000 after purchasing an additional 820,587 shares in the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Revance Therapeutics in the fourth quarter valued at approximately $171,000. Finally, Aigen Investment Management LP bought a new stake in shares of Revance Therapeutics in the fourth quarter valued at approximately $172,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Trading Up 8.5 %

Revance Therapeutics stock traded up $0.29 during mid-day trading on Monday, reaching $3.69. The company had a trading volume of 3,223,713 shares, compared to its average volume of 1,820,454. The business has a fifty day simple moving average of $4.95 and a 200 day simple moving average of $6.42. The company has a market cap of $384.57 million, a P/E ratio of -0.97 and a beta of 1.06. Revance Therapeutics, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $37.98.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.17. The firm had revenue of $69.80 million for the quarter, compared to analyst estimates of $64.02 million. Research analysts forecast that Revance Therapeutics, Inc. will post -2.17 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Barclays reduced their target price on Revance Therapeutics from $35.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, January 29th. Needham & Company LLC dropped their target price on shares of Revance Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. The Goldman Sachs Group increased their price target on shares of Revance Therapeutics from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, March 1st. Piper Sandler lowered their price objective on shares of Revance Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, February 29th. Finally, Mizuho downgraded Revance Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $16.00 to $9.00 in a report on Monday, January 29th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Revance Therapeutics currently has a consensus rating of “Hold” and an average target price of $13.75.

Insider Buying and Selling at Revance Therapeutics

In related news, insider Dwight Moxie sold 8,125 shares of Revance Therapeutics stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $40,950.00. Following the sale, the insider now directly owns 137,815 shares in the company, valued at approximately $694,587.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Tobin Schilke sold 9,361 shares of Revance Therapeutics stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $47,179.44. Following the transaction, the chief financial officer now directly owns 192,666 shares of the company’s stock, valued at $971,036.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Dwight Moxie sold 8,125 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $40,950.00. Following the sale, the insider now directly owns 137,815 shares of the company’s stock, valued at approximately $694,587.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,089 shares of company stock worth $143,642. 3.50% of the stock is currently owned by insiders.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.